Available tools to facilitate early patient access to medicines in the EU and the USA

Analysis of conditional approvals and the implications for personalized medicine

Lada Leyens, Étienne Richer, Øyvind Melien, Wolfgang Ballensiefen, Angela Brand

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Scientific knowledge and our understanding of the human body and diseases have limited any possible treatment tailoring to each patient. The technological advances enabling the integration of various data sets (e.g. '-omics', microbiome, epigenetics and environmental exposure) have facilitated a greater understanding of the human body, the molecular basis of disease and all the factors influencing disease onset, progression and response to treatment, thereby ushering in the era of personalized medicine. We evaluate the regulatory approaches available to facilitate early patient access to efficacious and safe compounds in the EU and the USA in order to make more informed recommendations in the future as to the gaps in regulations for early patient access. An in-depth analysis of conditional approvals (EU) and accelerated approvals (USA) is performed based on the publicly available information (European public assessment reports and a summary review of products approved under both programmes). The types of product, indications, time to approval and type of evidence submitted were analysed. Between 2007 and early 2015, 17 products were conditionally approved in the EU and 25 in the USA, most of them in the area of oncology and based on evidence from phase II clinical trial data. Early approval of promising products based on data from early phases of development is already possible in the EU and the USA. Some of the improvements could entail implementing a rolling assessment of evidence in Europe and extending the scope of early dialogues.

Original languageEnglish
Pages (from-to)249-259
Number of pages11
JournalPublic Health Genomics
Volume18
Issue number5
DOIs
Publication statusPublished - 08-10-2015

Fingerprint

Precision Medicine
Human Body
Consumer Product Safety
Phase II Clinical Trials
Microbiota
Environmental Exposure
Epigenomics
Disease Progression
Therapeutics

All Science Journal Classification (ASJC) codes

  • Public Health, Environmental and Occupational Health
  • Genetics(clinical)

Cite this

@article{110c83c581234705a84010abfc1e38bd,
title = "Available tools to facilitate early patient access to medicines in the EU and the USA: Analysis of conditional approvals and the implications for personalized medicine",
abstract = "Scientific knowledge and our understanding of the human body and diseases have limited any possible treatment tailoring to each patient. The technological advances enabling the integration of various data sets (e.g. '-omics', microbiome, epigenetics and environmental exposure) have facilitated a greater understanding of the human body, the molecular basis of disease and all the factors influencing disease onset, progression and response to treatment, thereby ushering in the era of personalized medicine. We evaluate the regulatory approaches available to facilitate early patient access to efficacious and safe compounds in the EU and the USA in order to make more informed recommendations in the future as to the gaps in regulations for early patient access. An in-depth analysis of conditional approvals (EU) and accelerated approvals (USA) is performed based on the publicly available information (European public assessment reports and a summary review of products approved under both programmes). The types of product, indications, time to approval and type of evidence submitted were analysed. Between 2007 and early 2015, 17 products were conditionally approved in the EU and 25 in the USA, most of them in the area of oncology and based on evidence from phase II clinical trial data. Early approval of promising products based on data from early phases of development is already possible in the EU and the USA. Some of the improvements could entail implementing a rolling assessment of evidence in Europe and extending the scope of early dialogues.",
author = "Lada Leyens and {\'E}tienne Richer and {\O}yvind Melien and Wolfgang Ballensiefen and Angela Brand",
year = "2015",
month = "10",
day = "8",
doi = "10.1159/000437137",
language = "English",
volume = "18",
pages = "249--259",
journal = "Public Health Genomics",
issn = "1662-4246",
publisher = "S. Karger AG",
number = "5",

}

Available tools to facilitate early patient access to medicines in the EU and the USA : Analysis of conditional approvals and the implications for personalized medicine. / Leyens, Lada; Richer, Étienne; Melien, Øyvind; Ballensiefen, Wolfgang; Brand, Angela.

In: Public Health Genomics, Vol. 18, No. 5, 08.10.2015, p. 249-259.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Available tools to facilitate early patient access to medicines in the EU and the USA

T2 - Analysis of conditional approvals and the implications for personalized medicine

AU - Leyens, Lada

AU - Richer, Étienne

AU - Melien, Øyvind

AU - Ballensiefen, Wolfgang

AU - Brand, Angela

PY - 2015/10/8

Y1 - 2015/10/8

N2 - Scientific knowledge and our understanding of the human body and diseases have limited any possible treatment tailoring to each patient. The technological advances enabling the integration of various data sets (e.g. '-omics', microbiome, epigenetics and environmental exposure) have facilitated a greater understanding of the human body, the molecular basis of disease and all the factors influencing disease onset, progression and response to treatment, thereby ushering in the era of personalized medicine. We evaluate the regulatory approaches available to facilitate early patient access to efficacious and safe compounds in the EU and the USA in order to make more informed recommendations in the future as to the gaps in regulations for early patient access. An in-depth analysis of conditional approvals (EU) and accelerated approvals (USA) is performed based on the publicly available information (European public assessment reports and a summary review of products approved under both programmes). The types of product, indications, time to approval and type of evidence submitted were analysed. Between 2007 and early 2015, 17 products were conditionally approved in the EU and 25 in the USA, most of them in the area of oncology and based on evidence from phase II clinical trial data. Early approval of promising products based on data from early phases of development is already possible in the EU and the USA. Some of the improvements could entail implementing a rolling assessment of evidence in Europe and extending the scope of early dialogues.

AB - Scientific knowledge and our understanding of the human body and diseases have limited any possible treatment tailoring to each patient. The technological advances enabling the integration of various data sets (e.g. '-omics', microbiome, epigenetics and environmental exposure) have facilitated a greater understanding of the human body, the molecular basis of disease and all the factors influencing disease onset, progression and response to treatment, thereby ushering in the era of personalized medicine. We evaluate the regulatory approaches available to facilitate early patient access to efficacious and safe compounds in the EU and the USA in order to make more informed recommendations in the future as to the gaps in regulations for early patient access. An in-depth analysis of conditional approvals (EU) and accelerated approvals (USA) is performed based on the publicly available information (European public assessment reports and a summary review of products approved under both programmes). The types of product, indications, time to approval and type of evidence submitted were analysed. Between 2007 and early 2015, 17 products were conditionally approved in the EU and 25 in the USA, most of them in the area of oncology and based on evidence from phase II clinical trial data. Early approval of promising products based on data from early phases of development is already possible in the EU and the USA. Some of the improvements could entail implementing a rolling assessment of evidence in Europe and extending the scope of early dialogues.

UR - http://www.scopus.com/inward/record.url?scp=84945479824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945479824&partnerID=8YFLogxK

U2 - 10.1159/000437137

DO - 10.1159/000437137

M3 - Article

VL - 18

SP - 249

EP - 259

JO - Public Health Genomics

JF - Public Health Genomics

SN - 1662-4246

IS - 5

ER -